FDA alignment, AbbVie milestone, and $100M offering reshape Regenxbio's outlook
FDA alignment for Navsunli accelerated approval Regenxbio aligned with the FDA on accelerated approval for Navsunli (MPS II gene therapy), with no additional studies needed. The company plans to resubmit its application in Q3 2026. This regulatory clarity removes a major overhang and raises the chance of approval, pushing the stock up.
This is a new regulatory development that directly boosts approval prospects and investor confidence.
AbbVie milestone and trial start for diabetic retinopathy gene therapy Regenxbio dosed the first patient in a Phase IIb/III trial of surabgene lomparvovec for diabetic retinopathy, triggering a $100 million milestone payment from AbbVie. This validates the program and brings non-dilutive cash, supporting the stock.
New clinical progress and partnership milestone provide both validation and cash, key positive drivers.
$100 million public offering dilutes shareholders Regenxbio priced a $100 million public offering of common stock and pre-funded warrants at $9.00 per share, sending shares down about 20%. The offering dilutes existing shareholders and signals a need for cash, pressuring the stock.
This is a new capital raise that directly dilutes ownership and caused a sharp negative price reaction.
Cash runway extended into Q4 2027 after milestone and offering Regenxbio ended Q2 with $106 million in cash, pro forma over $310 million after the AbbVie milestone and offering proceeds, extending its cash runway into Q4 2027. This reduces near-term financing risk and supports ongoing trials.
New financial update shows improved liquidity, a key positive for a clinical-stage biotech.